{"name":"CatalYm GmbH","slug":"catalym-gmbh","ticker":"","exchange":"","domain":"catalymgmbh.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Carboplatin AUC 5","genericName":"Carboplatin AUC 5","slug":"carboplatin-auc-5","indication":"Ovarian cancer","status":"phase_2"}]}],"pipeline":[{"name":"Carboplatin AUC 5","genericName":"Carboplatin AUC 5","slug":"carboplatin-auc-5","phase":"phase_2","mechanism":"Alkylating agent that interferes with DNA replication","indications":["Ovarian cancer","Breast cancer","Lung cancer"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixgJBVV95cUxOcVp3MFpZMWhhR2hKUVZTb1FDQk9kS1dvdnZBelJpMDdzSjJSS2p4YVcwRldPSnhibnFmclI1cUp1dGVBdTlEZEd4Ty1Dbk1NQzlhVHFsRXJHdzRpN1dSSnNVREJUTktmeTl1ejk0N3psa3NYR3N1aVdodnlCUlE2ZHNVMzd5a2QySkJfRVBJSGw1UGJtTHZvRUVDdGl2Y2V2b1JuTDRQTUFCRTlGRWg5alVieUxDSXVJV1dwN0tKYVBEMkliT1pGS3BFQklCQUxFdWZTUXgtM3JTckdDSEJtMWFSTVB5WjJzM1BoZXprdm1rRnRVM1lzM2p4NzNsTk1yNVU1SkNVQVE5amVSMWFuQXA3M2VNSkVlODQ0VDV0YzZEbjBzLWJDSnV5UlN6c3pfM2FOMHVxLUQyYlFLcmVoMnRtc2FPZw?oc=5","date":"2026-04-07","type":"trial","source":"BioSpace","summary":"CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma - BioSpace","headline":"CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Lin","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiuwJBVV95cUxOOEtoUkRsa2F3a0dUc2RHVXl1N3B0VGEtbjJVUW90ZW9oQ3BVbHhsOC1lSGVYS1loRjFPcmNzM1Vyb0I5by1tZHRDV0JHZTJsWkwzZkNzdXJIMFNMbi1PWVVTb1BYbXdLYmZjM2NMbUNRU19QZVkxZXpodWZHVEdLM01uUk8zM3ZPUUlXZnZGb2Z3MldITUNEN2d6amM5bmY5ZF9JZDRVT0psVUdFZ3pYaVQzVG82ZGV1anc1U1NJMk9SQ1ZsWU1iMWRFWWItaVlBekRSUUFHSER3VVFpYzRxdkI0Wm1WUWlDeVItcV83c1BfSE81eVFCd1I1MU51ZG9ScE16bTdZaXpyVkJSR003clNuVHR3WEVxckwzRTFHVlpPTFFTcmU4QkZ5TmNhZnkzQ2s5c1RCZE53SUk?oc=5","date":"2025-10-20","type":"trial","source":"BioSpace","summary":"CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO - BioSpace","headline":"CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity fo","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxORFhiNk5FVEVSaXVVaUt5VnZGTmhucDNpYXFveW1EQ0hEd1RXdjMzSjJ3N1ItQzZrNW5Pb2xqYUdMU3FMblFGajhnVW5qZ3kyYUZmc2t2OEhBOWtjM2owMVdBbUVLZkR4Wk9GRDdhOFFHc2NfOFBhMkVUbFllU3FfMGxiN19sdkhzQXYxb2YweWUzSkJWWEE0bw?oc=5","date":"2025-09-15","type":"pipeline","source":"Yahoo Finance","summary":"CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development - Yahoo Finance","headline":"CatalYm Announces Leadership Changes to Accelerate Visugromab Late-stage Clinical Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQU25aSXpuUUFjbGtncmVGTDBrVnJWSUZlR1M3Z2dwOVhnWmRrYlZwTnViUHUzY2FhMWV0VkIwcktFVXNSN01WSHJhQW9GS0d4RkxsS0FpRVl0bURaN0JHaWhuRVFUbDV0VzE0NEdVVC1CQUN1R1lTd0FDalllUWlycllMc2E3d0dSTWNtaA?oc=5","date":"2025-08-15","type":"trial","source":"Oncology Pipeline","summary":"CatalYm joins Pfizer in pivotal cachexia push | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"CatalYm joins Pfizer in pivotal cachexia push | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxQQWFIdHpSVW04Y1dhT0pwMXVoLWVpVHJWNHRjYzFJQVJZNk1ITkVlbVdZaWQyZVd0OHlmWTFhWm1GYUY4dFNWS1I2Rmh0VXk4azd3UFFkSm1CeGtkZURlZVV3YkdyWVJRVUhUcFJxeHRXNndPRmlhdlktcVp1ajZFNFFEUm5RZXdjMXdKaG1kdldWdlJzdDNCRUkxaUMwdGg3blRkZXJpLVpmQjJYT3VEdmxWd2UxdnExcGtqMUdjTjJ5ejB5NEVoRkFrOVJiTFgyRHAtbkhwSHhoZ1VXVmQzMXJMVVFJUDJDSHc?oc=5","date":"2025-01-09","type":"trial","source":"BioSpace","summary":"CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab - BioSpace","headline":"CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxPR21HRzh5Rksya1IxMFhMaWdUQV9VOWF2MFhzOC14YllYVFJVQUVJejRWT21zR0VoWmlJcmZwN2VyQlVBd2lhWWpBZFhEQlNBRnE2UERJenU3cDZ1STI3S0J0TzM4cGVDTlVFU2V4SE1aNld6WWI0VWhjeXBsbGpFSHE3TC1tcVg2YnpRTUVTUXFCazluMFEwU213ZlYwUGVQYXhQR1h1NnJHYUJi?oc=5","date":"2024-07-16","type":"trial","source":"Fierce Biotech","summary":"German biotech CatalYm cashes in on early-stage cancer data with $150M series D - Fierce Biotech","headline":"German biotech CatalYm cashes in on early-stage cancer data with $150M series D","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMieEFVX3lxTE11RVBxUnVlQmROWDVaN0k1MjJWRVhYek82UFlwWHJMSDBzQ1ZHRmlmVzVXWXpfeERtTWxsdVNIaEpLaW9ZWldZU1p5QVFXbkxOTDlDWGhGQ0ZZcndnRTJYOXU3UDdtVHJ6UDJZdDY0VHgtTG5fd1c1Uw?oc=5","date":"2024-07-15","type":"pipeline","source":"European Biotechnology Magazine","summary":"Catalym raises US$150m - European Biotechnology Magazine","headline":"Catalym raises US$150m","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8AFBVV95cUxOdWRjZFRIM0x6TmlEMDM4MkpCb294WmoxbWY0eERTZXZEel94WUUtUURxLUVOdUlIV3libzJDQ2dialpFcjVVV2hqZHQwVzFFbVU0WHByc2VwSjd0X0RBck5FUG1MOHA1RllBckZIUGN0ZjBmM3JsWm1Hc0d5Q1NLc2xWcGVGbXM2WGN4Q1Y1cmNqWUNvTUxsZWZuVmtIMHA5RXBtRXdkWXRmQWgzSGhhUGI5dGI1UXJLRDdKeDVtY1NkdWxheEwzTWlBbWl3enMwbjJwR3N3em9tXzkwLS1WSWNZRk1aLUx1S1I3S0FyeFU?oc=5","date":"2023-10-15","type":"trial","source":"The AI Journal","summary":"CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Immune Cell Activation - The AI Journal","headline":"CatalYm Presents Data at ESMO 2023 Expanding GDF-15’s Role in Checkpoint Therapy Resistance by Inhibition of Myeloid Imm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiW0FVX3lxTE9UeHhpQlJvblUta3R3eC03eHN6eUxHNEt4RXFrX1hiakdHYlU3RWdNODlyMTlGa0NYREVDem9pTGhySDRYOE1kMjdfdm83RXhMWGRJLWFRTURFR2c?oc=5","date":"2023-07-20","type":"trial","source":"EurekAlert!","summary":"CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance - EurekAlert!","headline":"CatalYm publishes data in Nature Communications describing gdf-15 as a central factor of anti-PD-1 resistance - EurekAle","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}